Coherus Oncology (CHRS) Total Non-Current Liabilities (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Total Non-Current Liabilities data on file, last reported at $170.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 67.43% year-over-year to $170.4 million; the trailing twelve-month figure through Mar 2026 stood at $170.4 million (down 67.43% YoY), and the FY2025 full-year result was $195.5 million, down 64.53% from the prior year.
• Total Non-Current Liabilities declined to $170.4 million in Q1 2026, from $195.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $844.8 million in Q1 2024 to a low of $170.4 million in Q1 2026.
• A 5-year average of $560.0 million and a median of $592.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 41.07% in 2024 and plunged 67.43% in 2026, its largest moves.
• Tracing CHRS's Total Non-Current Liabilities over 5 years: stood at $614.8 million in 2022, then jumped by 31.83% to $810.5 million in 2023, then slumped by 31.99% to $551.2 million in 2024, then tumbled by 64.53% to $195.5 million in 2025, then fell by 12.83% to $170.4 million in 2026.
• Business Quant data shows CHRS's Total Non-Current Liabilities at $170.4 million in Q1 2026, $195.5 million in Q4 2025, and $428.6 million in Q3 2025.